[ET Net News Agency, 15 December 2025] Morgan Stanley raised the target price for Ali Health (00241) to HKD4.6 from HKD4.2 and maintained the "underweight" rating.
The research house said it raises FY26-28e revenue by 5.5%/6.7%/7.1%, respectively, reflecting the strong sales momentum in the online drug segment and the updated company guidance. (rc)
The research house said it raises FY26-28e revenue by 5.5%/6.7%/7.1%, respectively, reflecting the strong sales momentum in the online drug segment and the updated company guidance. (rc)